908 Devices (MASS) Stock Price, News & Analysis

Company Overview

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $6.46 to $6.79
• 50-Day Range: $5.76 to $7.97
• 52-Week Range: $1.81 to $8.06
• Volume: 366,644 shs
• Average Volume: 1.62 million shs
• Market Capitalization: $235.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

908 Devices Stock Analysis - MarketRank™

908 Devices scored higher than 60% of companies evaluated by MarketBeat, and ranked 628th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Buy

Consensus Rating

908 Devices has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

908 Devices has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 908 Devices are expected to grow in the coming year, from ($1.99) to ($1.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 908 Devices is -12.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 908 Devices is -12.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

908 Devices has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.23% of the float of 908 Devices has been sold short.

Short Interest Ratio / Days to Cover

908 Devices has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 908 Devices has recently decreased by 13.60%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

908 Devices does not currently pay a dividend.

Dividend Growth

908 Devices does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.23% of the float of 908 Devices has been sold short.

Short Interest Ratio / Days to Cover

908 Devices has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 908 Devices has recently decreased by 13.60%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.19

News Sentiment

908 Devices has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for 908 Devices this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for MASS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 908 Devices insiders have sold 445.20% more of their company's stock than they have bought. Specifically, they have bought $42,900.00 in company stock and sold $233,890.00 in company stock.

Percentage Held by Insiders

23.70% of the stock of 908 Devices is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.06% of the stock of 908 Devices is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MASS Stock Analysis - Frequently Asked Questions

How have MASS shares performed this year?

908 Devices' stock was trading at $2.20 at the beginning of the year. Since then, MASS stock has increased by 199.5% and is now trading at $6.59.

How were 908 Devices' earnings last quarter?

908 Devices Inc. (NASDAQ:MASS) released its earnings results on Tuesday, May, 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. The business had revenue of $11.78 million for the quarter, compared to the consensus estimate of $11.90 million. 908 Devices had a negative net margin of 28.80% and a negative trailing twelve-month return on equity of 27.10%.
Read the conference call transcript.

When did 908 Devices IPO?

908 Devices (MASS) raised $101 million in an initial public offering on Friday, December 18th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. Cowen, SVB Leerink, Stifel and William Blair acted as the underwriters for the IPO.

Who are 908 Devices' major shareholders?

908 Devices' top institutional shareholders include ARK Investment Management LLC (7.39%), Sumitomo Mitsui Trust Group Inc. (1.11%), Old Port Advisors (0.21%) and IQ EQ FUND MANAGEMENT IRELAND Ltd (0.11%). Insiders that own company stock include Christopher D Brown, Kevin J Knopp, Joseph H Iv Griffith, Mark Spoto and Michael S Turner.
View institutional ownership trends.

How do I buy shares of 908 Devices?

Shares of MASS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 908 Devices own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 908 Devices investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:MASS
• CIK: 1555279
• Web: www.908devices.com
• Phone: 857-254-1500
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for 908 Devices: $8.00
• High Price Target: $12.00
• Low Price Target: $6.00
• Potential Upside/Downside: +21.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$72.21 million
• Net Margins: -28.80%
• Pretax Margin: -124.44%
• Return on Equity: -27.10%
• Return on Assets: -20.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.62
• Quick Ratio: 6.97

Sales & Book Value

• Annual Sales: $59.63 million
• Price / Sales: 3.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.29 per share
• Price / Book: 2.00

Miscellaneous

• Outstanding Shares: 35,860,000
• Free Float: 27,362,000
• Market Cap: $235.78 million
• Optionable: Optionable
• Beta: 0.37